Protocols›Metabolic & fat loss›Belly Fat — Summer Cut
← Protocols
POM · prescription medicinesRCT-backed · parts, not combinationSpot reduction is not real

Belly Fat — Summer Cut

Stack: Tesamorelin + Semaglutide + AOD-9604 · abdominal / visceral fat
"The honest version of a summer cut. Tesamorelin is the only one here with belly-specific (visceral-fat) trial data; a GLP-1 drives real systemic loss; AOD-9604 is the hyped fat-burner that failed its obesity trials. You cannot spot-reduce belly fat by injecting it — fat loss is systemic."
GoalAbdominal / visceral fat
Compounds3 · Tesamorelin + Semaglutide + AOD-9604
Humans exposed (est.)High (Tesamorelin, Semaglutide — approved drugs)
StatusUK: Tesamorelin & Semaglutide are prescription-only medicines (POM, .uk-pom) — buying/supplying without a prescription is an offence · AOD-9604: research material · Combination is not an approved therapy
In this stack — snapshot; tap through for the full molecule file
Provenance & evidence layers — of the combination, not the parts
Evidenced — but for visceral fat
What has data
Tesamorelin (a GHRH analog, FDA-approved as Egrifta) has randomised-trial evidence for reducing visceral abdominal fat. Semaglutide has large RCTs for systemic weight loss.
What it means for belly fat
Tesamorelin lowers deep abdominal fat via the GH axis — a systemic effect, not because it is injected near the belly.
Evidence it adds
Genuine human efficacy for the individual drugs.
Basis: approved drugs with RCT evidence (Tesamorelin, Semaglutide)
Spot reduction is not real
The myth
Injecting a “fat-burner” into the belly does not preferentially burn belly fat. Fat is mobilised systemically through energy balance — local injection site does not direct where fat is lost.
AOD-9604
The marketed lipolytic GH-fragment failed its Phase 2 obesity trials — no better than placebo for weight loss. Included here only because community stacks use it; the evidence does not support it.
Basis: physiology + failed AOD-9604 obesity trials — myth shown, not sold
Regulatory — read carefully
UK (MHRA)
Tesamorelin and Semaglutide are prescription-only medicines. Supplying or buying them without a prescription is unlawful in the UK.
AOD-9604
Sold as a research chemical — not a licensed medicine.
What it means
This is the AMBER tier — POMs are involved. The legal route to Tesamorelin/Semaglutide is a clinician and a pharmacy.
Why it matters
Grey-market GLP-1/GHRH carry dosing, purity and counterfeit risks on top of the legal exposure.
Basis: UK POM status (Tesamorelin, Semaglutide)
Why this combination

The honest hierarchy: Tesamorelin is the only compound here with trial evidence aimed at abdominal (visceral) fat specifically. Semaglutide produces large, real systemic weight loss — belly fat falls as part of overall loss, not selectively. AOD-9604 is the hyped “lipolytic” that did not beat placebo in obesity trials. There is no peptide that melts belly fat on its own, and none that spot-reduces. Diet, training and overall energy balance remain the engine; these are adjuncts at best. Free information is full; actionable depth is gated.

Members only · the actionable depth
See exactly how it's run
Doses, cycle structure and what to monitor are part of membership. The provenance, evidence and exposure above are always free.
Start 30 days free →
No card needed · cancel anytime
Cycle shape — how it's typically structured, not a schedule to follow
Loading
build up
Maintenance
hold / taper
Off
stop / reassess
Convention from community use, not a prescription.
What's worth monitoring

If a clinician is involved, the GH axis and metabolic markers are the ones that matter here: fasting glucose and HbA1c (GHRH analogs can nudge insulin resistance), IGF-1, and standard lipids/blood pressure. GLP-1 use brings its own GI tolerance and, rarely, pancreatitis considerations. None of this is a green light — it is what a careful clinician would track. General information, not medical advice.

Combination evidence
Visceral-fat efficacy Strong (Tesamorelin)

RCT evidence for reducing deep abdominal fat — systemically, via the GH axis.

AOD-9604 None

Failed Phase 2 obesity trials — no better than placebo.

The honest ceiling

No peptide spot-reduces belly fat. Energy balance is the engine; these are adjuncts, two of them prescription-only.

Fast facts
Compounds

Tesamorelin · Semaglutide · AOD-9604

Humans exposed (est.)

High (Tesamorelin, Semaglutide — approved).

UK strip

AMBER — contains POMs (Tesamorelin, Semaglutide)